UY25713A1 - Método para tratar diabetes empleando un inhibidor ap2 y combinación. - Google Patents
Método para tratar diabetes empleando un inhibidor ap2 y combinación.Info
- Publication number
- UY25713A1 UY25713A1 UY25713A UY25713A UY25713A1 UY 25713 A1 UY25713 A1 UY 25713A1 UY 25713 A UY25713 A UY 25713A UY 25713 A UY25713 A UY 25713A UY 25713 A1 UY25713 A1 UY 25713A1
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitor
- combination
- treating diabetes
- diabetes
- glyburide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
- 229960001641 troglitazone Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Se provee un método para tratar la diabetes y enfermedades relacionadas, específicamente la diabetes de Tipo II, empleando un inhibidor ap2 o una combinación de un inhibidor ap2 y otro agente antidiabético tal como metformina, gliburida, troglitazona y/o insulina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10067798P | 1998-09-17 | 1998-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25713A1 true UY25713A1 (es) | 2001-08-27 |
Family
ID=22280975
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25714A UY25714A1 (es) | 1998-09-17 | 1999-09-16 | Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación. |
UY25713A UY25713A1 (es) | 1998-09-17 | 1999-09-16 | Método para tratar diabetes empleando un inhibidor ap2 y combinación. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25714A UY25714A1 (es) | 1998-09-17 | 1999-09-16 | Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación. |
Country Status (30)
Country | Link |
---|---|
US (1) | US20020035064A1 (es) |
EP (2) | EP1113801A4 (es) |
JP (2) | JP2002524517A (es) |
KR (2) | KR20010079842A (es) |
CN (2) | CN1319012A (es) |
AT (1) | ATE406898T1 (es) |
AU (2) | AU754488B2 (es) |
BG (2) | BG105431A (es) |
BR (2) | BR9913833A (es) |
CA (2) | CA2344309A1 (es) |
CO (2) | CO5130025A1 (es) |
CZ (2) | CZ2001964A3 (es) |
DE (1) | DE69939481D1 (es) |
EE (2) | EE04356B1 (es) |
ES (1) | ES2311306T3 (es) |
GE (2) | GEP20033044B (es) |
HU (2) | HUP0104240A2 (es) |
ID (2) | ID27833A (es) |
IL (2) | IL141785A0 (es) |
LT (2) | LT4871B (es) |
LV (2) | LV12686B (es) |
NO (2) | NO20011351L (es) |
NZ (2) | NZ510209A (es) |
PE (2) | PE20001056A1 (es) |
PL (2) | PL346660A1 (es) |
SK (1) | SK3202001A3 (es) |
TR (2) | TR200100773T2 (es) |
UY (2) | UY25714A1 (es) |
WO (2) | WO2000015229A1 (es) |
ZA (2) | ZA200207433B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1047423B1 (en) * | 1997-11-19 | 2006-05-10 | Takeda Pharmaceutical Company Limited | Novel apoptosis inhibitors |
AU2005201289B2 (en) * | 1999-02-12 | 2008-04-17 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions |
ATE419346T1 (de) * | 1999-02-12 | 2009-01-15 | Harvard College | Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
JP2004501066A (ja) | 2000-01-28 | 2004-01-15 | ブリストル−マイヤーズ スクイブ カンパニー | 脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法 |
HUP0500543A2 (hu) * | 2000-11-20 | 2005-09-28 | Bristol-Myers Squibb Company | Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények |
CA2439063A1 (en) * | 2001-03-12 | 2002-09-19 | Novartis Ag | Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
WO2003006023A1 (en) | 2001-07-13 | 2003-01-23 | Bristol-Myers Squibb Company | Pyrazinone inhibitors of fatty acid binding protein and method |
WO2003007888A2 (en) * | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
AU2002348276A1 (en) | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
CA2513102C (en) | 2003-01-27 | 2011-03-22 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
AU2004224825A1 (en) * | 2003-03-26 | 2004-10-07 | Crc For Asthma Limited | Therapeutic and prophylactic compositions and uses therefor |
WO2004096977A2 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof |
SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
JP4108739B2 (ja) | 2004-06-04 | 2008-06-25 | メルク エンド カムパニー インコーポレーテッド | ピラゾール誘導体、かかる化合物を含む組成物及び使用方法 |
MX2007009888A (es) | 2005-02-17 | 2007-10-16 | Synta Pharmaceuticals Corp | Compuestos para el tratamiento de trastornos proliferativos. |
CA2614537A1 (en) | 2005-07-26 | 2007-02-08 | Merck & Co., Inc. | Process for synthesizing a substituted pyrazole |
AU2006304689A1 (en) * | 2005-10-18 | 2007-04-26 | Aegerion Pharmaceuticals | Compositions for lowering serum cholesterol and/or triglycerides |
WO2007143164A1 (en) * | 2006-06-02 | 2007-12-13 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
JP2012508692A (ja) * | 2008-11-12 | 2012-04-12 | シェーリング コーポレイション | 脂肪酸結合タンパク質(fabp)の阻害薬 |
CN102639149A (zh) * | 2009-03-05 | 2012-08-15 | 哈佛学院董事会 | 分泌的aP2及其抑制方法 |
JP6514282B2 (ja) * | 2014-03-24 | 2019-05-15 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
JP6223376B2 (ja) | 2014-03-24 | 2017-11-01 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
EP3288584A2 (en) | 2015-04-30 | 2018-03-07 | President and Fellows of Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
JP7038707B2 (ja) * | 2016-06-27 | 2022-03-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害の治療に有用な化合物 |
AU2018279950A1 (en) | 2017-06-09 | 2020-01-30 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2129012A1 (de) | 1971-06-11 | 1973-01-04 | Merck Patent Gmbh | Azol-derivate |
FR2156486A1 (en) | 1971-10-22 | 1973-06-01 | Roussel Uclaf | Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories |
JPS5612114B2 (es) | 1974-06-07 | 1981-03-18 | ||
GB1507032A (en) | 1974-08-06 | 1978-04-12 | Serono Lab | 2-thiol-4,5-diphenyloxazole s-derivatives |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
DK277488A (da) | 1987-05-22 | 1988-11-23 | Squibb & Sons Inc | Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen |
FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
US5218124A (en) * | 1989-10-27 | 1993-06-08 | American Home Products Corporation | Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase |
PT95690A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase |
US5262540A (en) * | 1989-12-20 | 1993-11-16 | Bristol-Myers Squibb Company | [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters |
FR2663331B1 (fr) | 1990-06-14 | 1994-05-06 | Bellon Laboratoires | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
GB9019841D0 (en) * | 1990-09-11 | 1990-10-24 | Smith Kline French Lab | Compounds |
US5254576A (en) * | 1992-04-03 | 1993-10-19 | Bristol-Myers Squibb Company | Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors |
US5348969A (en) * | 1992-04-03 | 1994-09-20 | Bristol-Myers Squibb Company | Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors |
US5187188A (en) * | 1992-04-03 | 1993-02-16 | Bristol-Myers Squibb Company | Oxazole carboxylic acid derivatives |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5362879A (en) * | 1993-04-15 | 1994-11-08 | Bristol-Myers Squibb Company | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
DE4340781C3 (de) | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
AU686286B2 (en) * | 1993-12-20 | 1998-02-05 | Fujisawa Pharmaceutical Co., Ltd. | 4,5-diaryloxazole derivatives |
US5599770A (en) | 1994-07-15 | 1997-02-04 | Kureha Kagaku Kogyo Kabushiki Kaisha | Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives |
BR9508468A (pt) | 1994-07-29 | 1997-11-25 | Smithkline Beecham Plc | Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
UA56992C2 (uk) | 1995-05-08 | 2003-06-16 | Фармація Енд Апджон Компані | <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
GB9600231D0 (en) | 1996-01-05 | 1996-03-06 | Foster Wheeler Petrol Dev Ltd | Spacing bouy for flexible risers |
AUPO134596A0 (en) | 1996-08-01 | 1996-08-22 | Jal Pastoral Co. Pty Ltd | Demountable article carrier for motor vehicles |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
-
1999
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Application Discontinuation
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Application Discontinuation
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/xx unknown
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-13 EE EEP200100154A patent/EE04356B1/xx not_active IP Right Cessation
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/xx unknown
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-13 EP EP99948210A patent/EP1113801A4/en not_active Withdrawn
- 1999-09-13 EP EP99951438A patent/EP1121129B1/en not_active Revoked
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Application Discontinuation
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 EE EEP200100155A patent/EE200100155A/xx unknown
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Application Discontinuation
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
-
2001
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
-
2002
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25713A1 (es) | Método para tratar diabetes empleando un inhibidor ap2 y combinación. | |
AR023388A1 (es) | INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO | |
UY34691A (es) | Inhibidores a base de pirrolidina fusionada con ciclopropilo de dipeptidil peptidasa iv y método | |
AR011829A1 (es) | Combinaciones para diabetes de sulfonilurea-glitazona. | |
AR017819A1 (es) | Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos | |
ECSP024397A (es) | Combinaciones de inihibidores de dipeptildil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus | |
DK1333887T3 (da) | Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler | |
EA200000041A1 (ru) | Способ лечения диабета тиазолидиндионом и метформином | |
BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
BR9913255A (pt) | Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto | |
MXPA03011981A (es) | 3-fluoruro-pirrolidinas como agentes antidiabeticos. | |
DK1011673T3 (da) | Hidtil ukendt metode til behandling af nidom | |
AR046210A1 (es) | Preparacion solida | |
BR0011339A (pt) | Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase | |
AR016350A1 (es) | Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos | |
ECSP993146A (es) | Metodo de tratameinto para la diabetes empleando un inhibidor ap2 y su combinacion | |
ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
BR9915214A (pt) | Combinações contendo um beta-agonista e umagente anti-diabético adicional | |
PE99799A1 (es) | Composicion farmaceutica para el tratamiento de la diabetes | |
DK1173437T3 (da) | Thiazolidinindionderivat og dets anvendelse som antidiabetisk middel | |
ECSP003408A (es) | INHIBIDORES DE aPz DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO | |
SE9302208L (sv) | Sätt vid dekontaminering | |
ES2156877T3 (es) | Anilidas de acidos cicloalquilcarboxilicos. | |
ES2174748B1 (es) | Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090520 |